GlassScriptPhysician profile
Ward C Zeno
NPI 1881980241
$6,727.65
in general payments reported to CMS, 2019-2025
30 companies · $1,492 in 2025
The $1,492 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,039 · 2020: $450 · 2021: $692 · 2022: $1,020 · 2023: $1,012 · 2024: $1,022 · 2025: $1,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,526.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,005.90 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $1,549.02 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $523.54 | 2019-2025 | Entyvio |
| Ardelyx, INC. | $514.69 | 2022-2025 | Ibsrela |
| Celgene Corporation | $326.39 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $247.46 | 2019-2025 | Tremfya, Simponi, Stelara |
| Celltrion USA INC. | $243.12 | 2024-2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $219.18 | 2024-2025 | Zenpep |
| Gilead Sciences, INC. | $191.22 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $145.38 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $125.53 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $70.04 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $68.98 | 2024-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $68.64 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $50.11 | 2025 | Iqirvo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $49.80 | 2024-2025 | |
| Evoke Pharma, INC. | $38.47 | 2021 | |
| Lilly USA, LLC | $35.54 | 2024-2025 | Omvoh |
| Exact Sciences Corporation | $32.42 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Braintree Laboratories, INC. | $31.68 | 2019-2023 | Sutab |
| Merck Sharp & Dohme LLC | $31.27 | 2020-2021 | |
| Genzyme Corporation | $24.99 | 2025 | |
| Romark Laboratories, Lc | $23.17 | 2019-2020 | |
| Echosens North America, INC. | $22.89 | 2025 | Fibroscan |
| Novo Nordisk INC | $17.43 | 2025 | Wegovy |
| Capsovision, INC. | $16.90 | 2025 | Capsocam Plus |
| Phathom Pharmaceuticals, INC. | $15.97 | 2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $13.56 | 2023 | Rebyota |
| Otsuka America Pharmaceutical, INC. | $13.27 | 2019 | |
| Boston Scientific Corporation | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ward Zeno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.